Close

Ampio (AMPE) Failure Another Positive for Flexion Therapeutics (FLXN) - Janney Montgomery Scott

June 30, 2016 12:11 PM EDT Send to a Friend
Janney Montgomery Scott analyst Ken Trbovich reiterated a Buy rating and $30 fair value price target on Flexion Therapeutics (NASDAQ ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login